“`html Table of Contents BREAKING: GLP-1 Access Improving, But Hurdles Remain Key Findings Limitations Noted Conclusion BREAKING: GLP-1 Access Improving, But Hurdles Remain By Amelia Smith | WASHINGTON… The post GLP-1 Coverage: Yearly Trends for Weight Loss 2024 appeared first on NewsyList. Source link
Researchers have used the US launch of tirzepatide, a dual glucagon-like peptide-1 receptor agonist (GLP-1 RA) and glucose-dependent insulinotropic polypeptide receptor agonist, as the dividing point to study trends in the use of glucose-lowering medications (GLMs) and weight-lowering medications (WLMs) using commercial insurance claim data. According to their findings published online today in Annals of … Read more
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its blockbuster molecule tirzepatide. Now, with a pipeline chock-full of numerous incretin therapies, the Big Pharma’s new strategy will be to test some of those drugs across neurology and immunology indications. “A new focus area first in 2025 will be to … Read more